How much revenue does TWi Biotechnology make?

TWi Biotechnology reported 0 TWD in revenue for fiscal year 2025.

TWi Biotechnology, Inc. (6610.TWO) Stock

About TWi Biotechnology, Inc.

TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; AC- 1101, which is in Phase Ib trial for th...

At a glance

TWi Biotechnology reported revenue of 0 TWD for fiscal year 2025, and net income of -357.52 million TWD.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.